Nanodelivery of doxorubicin for age-related macular degeneration

References

• Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2:e106–e116.
   PubMed Web of Science ®Google Scholar
• Villegas V, Aranguren L, Kovach J, et al. Current advances in the treatment of neovascular age-related macular degeneration. Exp Opin Drug Deliv. 2017;14:273–282.
   PubMed Web of Science ®Google Scholar
• Hirani A, Grover A, Lee YW, et al. Triamcinolone acetonide nanoparticles incorporated in thermoreversible gels for age-related macular degeneration. Pharm Dev Technol. 2016;21:61–67.
   PubMed Web of Science ®Google Scholar
• Ferrara N. Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol. 2009;29:789–791.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Kerbel R. Angiogenesis as a therapeutic target. Nature. 2005;438:967–974.
   PubMed Web of Science ®Google Scholar
• Subhani S, Vavilala DT, Mukherji M. HIF inhibitors for ischemic retinopathies and cancers: options beyond anti-VEGF therapies. Angiogenesis. 2016;19:257–273.
   PubMed Web of Science ®Google Scholar
• Cunningham M, Edelman J, Kaushal S. Intravitreal steroids for macular edema: the past, the present, and the future. Surv Ophthalmol. 2008;53:139–149.
   PubMed Web of Science ®Google Scholar
• Reichle M. Complications of intravitreal steroid injections. Optometry. 2005;76:450–460.
   PubMedGoogle Scholar
• Lux A, Llacer H, Heussen FM, et al. Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions. Br J Ophthalmol. 2007;91:1318–1322.
   PubMed Web of Science ®Google Scholar
• Schito L, Rey S, Tafani M, et al. Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells. Proc Natl Acad Sci USA. 2012;109:E2707–E2716.
   PubMed Web of Science ®Google Scholar
• Hu K, Babapoor-Farrokhran S, Rodrigues M, et al. Hypoxia-Inducible factor 1 upregulation of both VEGF and ANGPTL4 is required to promote the angiogenic phenotype in uveal melanoma. Oncotarget. 2016;7:7816–7828.
   PubMedGoogle Scholar
• Stefansson E, Geirsdottir A, Sigurdsson H. Metabolic physiology in age related macular degeneration. Prog Retin Eye Res. 2011;30:72–80.
   PubMed Web of Science ®Google Scholar
• Kurihara T, Westenskow PD, Gantner ML, et al. Hypoxia-induced metabolic stress in retinal pigment epithelial cells is sufficient to induce photoreceptor degeneration. Elife. 2016;5:e14319.
   PubMed Web of Science ®Google Scholar
• Krock BL, Skuli N, Simon MC. Hypoxia-induced angiogenesis: good and evil. Genes Cancer. 2011;2:1117–1133.
   PubMedGoogle Scholar
• Ziello J, Jovin I, Huang Y. Hypoxia-inducible factor (HIF)-1 regulatory pathway and its potential for therapeutic intervention in malignancy and ischemia. Yale J Biol Med. 2007;80:51–60.
   PubMedGoogle Scholar
• Yoshida D, Kim K, Noha M, et al. Hypoxia inducible factor 1-a regulates of plateletderived growth factor-B in human glioblastoma cells. J Neuro-Oncol. 2006;76:13–21.
   Google Scholar
• Kelly SJ, Halasz K, Sutariya V. HIF-1α inhibitors for the treatment of posterior. Int J Nanomed Nanosurg. 2017.
   Google Scholar
• Geldenhuys W, Wehrung D, Groshev A, et al. Brain-targeted delivery of doxorubicin using glutathione-coated nanoparticles for brain cancers. Pharm Dev Technol. 2015;20:497–506.
   PubMed Web of Science ®Google Scholar
• Khemani M, Sharon M, Sharon M. pH dependent encapsulation of doxorubicin in PLGA. Annal Biol Res. 2012;2012:4414–4419.
   Google Scholar
• Iwase T, Fu J, Yoshida T, et al. Sustained delivery of a HIF-1 antagonist for ocular neovascularization. J Control Release. 2013;172:625–633.
   PubMed Web of Science ®Google Scholar
• Berthold A, Cremer K, Kreuter J. Preparation and characterization of chitosan microspheres as drug carrier for prednisolone sodium phosphate as model for antiinflammatory drugs. J Control Release. 1996;39:17–25.
   Web of Science ®Google Scholar
• D’Souza SS, DeLuca PP. Development of a dialysis in vitro release method for biodegradable microspheres. AAPS PharmSciTech. 2005;6:E323–E328.
   PubMed Web of Science ®Google Scholar
• Hughes JM, Budd PM, Grieve A, et al. Highly monodisperse, lanthanide-containing polystyrene nanoparticles as potential standard reference materials for environmental “nano” fate analysis. J Appl Polym Sci. 2015;2015:42061.
   Google Scholar
• Stetefeld J, McKenna SA, Patel TR. Dynamic light scattering: a practical guide and applications in biomedical sciences. Biophys Rev. 2016;8:409–427.
   PubMedGoogle Scholar
• Gatoo MA, Naseem S, Arfat MY, et al. Physicochemical properties of nanomaterials: implication in associated toxic manifestations. Biomed Res Int. 2014;2014:1.
   Web of Science ®Google Scholar
• nanoComposix. Zeta potential analysis of nanoparticles. San Diego (CA): nanoComposix; 2012. p. 1–6.
   Google Scholar
• Madan JR, A KP, Dua K. Development and evaluation of solid lipid nanoparticles of mometasone furoate for topical delivery. Int J Pharm Investig. 2014;4:60–64.
   PubMedGoogle Scholar
• Li F, Hurley B, Liu Y, et al. Controlled release of bevacizumab through nanospheres for extended treatment of age-related macular degeneration. Open Ophthalmol J. 2012;6:54–58.
   PubMedGoogle Scholar
• Rabuffetti FA, Stair PC, Poeppelmeier KR. Synthesis-dependent surface acidity and structure of srTiO3 nanoparticles. J Phys Chem C. 2010;114:11056–11067.
   Google Scholar
• Breznan D, Das DD, O’Brien JS, et al. Differential cytotoxic and inflammatory potency of amorphous silicon dioxide nanoparticles of similar size in multiple cell lines. Nanotoxicology. 2017;11:223–235.
   PubMed Web of Science ®Google Scholar